Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
MAINZ, Germany, Sept. 06, 2017 (GLOBE NEWSWIRE) -- BioNTech AG, a fully integrated biotechnology company pioneering individualized cancer immunotherapy, today announced that it has entered into a...
-
MAINZ, Germany, July 05, 2017 (GLOBE NEWSWIRE) -- BioNTech AG, a fully-integrated biotechnology company pioneering individualized cancer immunotherapy, today announced Phase I trial results...
-
MAINZ, Germany, June 12, 2017 (GLOBE NEWSWIRE) -- BioNTech AG, a fully-integrated biotechnology company pioneering individualized cancer immunotherapy, reported preclinical data featuring a novel...
-
Mainz, June 12, 2017 (GLOBE NEWSWIRE) -- Die BioNTech AG, ein vollintegriertes Biotechnologieunternehmen, das personalisierte Krebsimmuntherapien entwickelt, gab heute präklinische Daten zu einer...
-
MAINZ, Germany, June 12, 2017 (GLOBE NEWSWIRE) -- BioNTech AG, a fully-integrated biotechnology company pioneering individualized cancer immunotherapy, reported preclinical data featuring a novel...
-
MAINZ, Germany, March 07, 2017 (GLOBE NEWSWIRE) -- BioNTech AG, a fully-integrated biotechnology company pioneering individualized cancer immunotherapy, today announced that it will present interim...
-
MAINZ, Germany, Feb. 22, 2017 (GLOBE NEWSWIRE) -- BioNTech AG, a fully integrated biotechnology company pioneering individualized cancer immunotherapy, today announced that Sean Marett, COO of...
-
MAINZ, Germany, Dec. 22, 2016 (GLOBE NEWSWIRE) -- BioNTech AG, a fully integrated biotechnology company developing truly individualized cancer immunotherapies, today announced that Sean Marett, COO...